Sponsored by
This is a new modality of treatment - antisense oligonucleotides. It worked for spinal muscular atrophy - which proves it can get and stay in the brain and spinal cord and make a big difference. They are now doing preclinical work on DIPG. We (The Musella Foundation) gave him his first grant to get started with DIPG back in 2016! Hopefully this will not only make a difference in DIPG, but the technology could be altered to work on most mutations.